Amarin_Logo_JPEG.jpg
Amarin to Present at H.C. Wainwright’s 24th Annual Global Investment Conference
August 30, 2022 08:00 ET | Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is...
Amarin_Logo_JPEG.jpg
New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers
August 28, 2022 05:51 ET | Amarin Corporation plc
-- Data Show VASCEPA/VAZKEPA Significantly Reduced First and Total Cardiovascular Events in Combined Current and Former Smokers by 23% and 29% Respectively Relative to Placebo in a Post Hoc Analysis...
Amarin_Logo_JPEG.jpg
New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes
August 26, 2022 08:19 ET | Amarin Corporation plc
-- Late-Breaking Data Show VASCEPA/VAZKEPA Significantly Reduced STEMI by 40% and NSTEMI by 27% in Pre-Specified, Post Hoc Analyses -- -- Data Presented During Late-Breaking Science Session at...
Amarin_Logo_JPEG.jpg
Latest Research Evaluating VASCEPA®/VAZKEPA (icosapent ethyl) and Subgroups from the REDUCE-IT® Landmark Outcomes Trial to be Presented at the European Society of Cardiology (ESC) Congress
August 15, 2022 08:00 ET | Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded research on the effects of VASCEPA®/VAZKEPA...
Amarin_Logo_JPEG.jpg
Amarin Reports Second Quarter 2022 Financial Results and Provides Business Update
August 03, 2022 07:00 ET | Amarin Corporation plc
Company Received Final Positive Reimbursement Decision for VAZKEPA® by UK’s NICE in England & Wales Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple...
Amarin_Logo_JPEG.jpg
Amarin to Report Second Quarter 2022 Financial Results and Host Conference Call on August 3, 2022
July 20, 2022 08:00 ET | Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., July 20, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior...
Amarin_Logo_JPEG.jpg
NICE Issues Final Guidance for Reimbursement Making VAZKEPA® (icosapent ethyl) Available Across the NHS in England & Wales
July 13, 2022 08:00 ET | Amarin Corporation plc
-- Newly published final guidance by the National Institute for Health and Care Excellence (NICE) in the UK confirms its prior draft recommendation for the use of VAZKEPA® (icosapent ethyl) in England...
Amarin_Logo_JPEG.jpg
REDUCE-IT Exploratory Post Hoc Biomarker Sub-Analysis Shows Relatively Small Changes in Inflammatory Markers Between Icosapent Ethyl and Placebo
June 30, 2022 16:05 ET | Amarin Corporation plc
-- Sub-Analysis Findings Support Prior Analyses that Eicosapentaenoic Acid (EPA) Level is The Major Determinant of Benefit in REDUCE-IT -- DUBLIN, Ireland and BRIDGEWATER, N.J., June 30, 2022 ...
Amarin_Logo_JPEG.jpg
Amarin Receives Positive Recommendation from United Kingdom’s (UK) National Institute for Health and Care Excellence (NICE) for Reimbursement of VAZKEPA® (icosapent ethyl)
June 10, 2022 06:00 ET | Amarin Corporation plc
UK’s NICE issued its draft Final Appraisal Document (FAD) recommending the use of VAZKEPA® (icosapent ethyl) in England and Wales to reduce the risk of cardiovascular (CV) events in adult...
Amarin_Logo_JPEG.jpg
Amarin Announces Comprehensive Cost Reduction Plan to Address Market Dynamics in U.S. Business
June 06, 2022 08:30 ET | Amarin Corporation plc
-- Company Expects to Achieve Approximately $100 Million in Cost Savings Over the Next 12 Months* While Continuing to Invest in European Launches and Global Expansion -- -- Reduces U.S. Commercial...